Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

What is it? A medication called semaglutide, which is sold under different brand names, including Ozempic, approved in 2017 for treating type 2 diabetes, and Wegovy, approved just last year for ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial ...

👋 Welcome to 5 Things PM! Hormonal birth control pills can be used to prevent pregnancy, and they’re also a popular way to go months or even years without a period. But is it safe? A ...

In a head-to-head diet-induced obese (DIO) mouse model, low dose ASC47 in combination with semaglutide demonstrated a 56.7% greater reduction in body weight with muscle preservation compared to ...

While GLP-1 receptor agonists (e.g., semaglutide, tirzepatide ... CG-0416 is a novel liver-targeted THR-β prodrug in development for MASH & obesity-related complications. Its tissue-selective ...